company background image
NXTM

Nexstim HLSE:NXTMH Stock Report

Last Price

€3.85

Market Cap

€25.8m

7D

-0.5%

1Y

-15.4%

Updated

23 Sep, 2022

Data

Company Financials +
NXTMH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance3/6
Financial Health5/6
Dividends0/6

NXTMH Stock Overview

Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.

Nexstim Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nexstim
Historical stock prices
Current Share Price€3.85
52 Week High€5.90
52 Week Low€3.62
Beta1.85
1 Month Change-12.40%
3 Month Change-8.33%
1 Year Change-15.38%
3 Year Change-72.00%
5 Year Change-99.48%
Change since IPO-99.98%

Recent News & Updates

Aug 20
Nexstim's (HEL:NXTMH) Promising Earnings May Rest On Soft Foundations

Nexstim's (HEL:NXTMH) Promising Earnings May Rest On Soft Foundations

Nexstim Plc ( HEL:NXTMH ) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders...

Aug 15
At €4.73, Is Nexstim Plc (HEL:NXTMH) Worth Looking At Closely?

At €4.73, Is Nexstim Plc (HEL:NXTMH) Worth Looking At Closely?

Nexstim Plc ( HEL:NXTMH ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...

Jun 14
Is Nexstim (HEL:NXTMH) A Risky Investment?

Is Nexstim (HEL:NXTMH) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

NXTMHFI Medical EquipmentFI Market
7D-0.5%-11.9%-5.8%
1Y-15.4%-40.0%-21.6%

Return vs Industry: NXTMH exceeded the Finnish Medical Equipment industry which returned -39.9% over the past year.

Return vs Market: NXTMH exceeded the Finnish Market which returned -20.7% over the past year.

Price Volatility

Is NXTMH's price volatile compared to industry and market?
NXTMH volatility
NXTMH Average Weekly Movement5.6%
Medical Equipment Industry Average Movement9.3%
Market Average Movement5.1%
10% most volatile stocks in FI Market8.2%
10% least volatile stocks in FI Market3.4%

Stable Share Price: NXTMH is not significantly more volatile than the rest of Finnish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: NXTMH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200039Mikko Karvinenhttps://www.nexstim.com

Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression and chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim Fundamentals Summary

How do Nexstim's earnings and revenue compare to its market cap?
NXTMH fundamental statistics
Market Cap€25.77m
Earnings (TTM)€3.32m
Revenue (TTM)€11.63m

7.8x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NXTMH income statement (TTM)
Revenue€11.63m
Cost of Revenue€1.22m
Gross Profit€10.40m
Other Expenses€7.08m
Earnings€3.32m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Feb 27, 2023

Earnings per share (EPS)0.50
Gross Margin89.49%
Net Profit Margin28.59%
Debt/Equity Ratio63.4%

How did NXTMH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NXTMH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NXTMH?

Other financial metrics that can be useful for relative valuation.

NXTMH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA10.8x
PEG Ratio-0.2x

Price to Earnings Ratio vs Peers

How does NXTMH's PE Ratio compare to its peers?

NXTMH PE Ratio vs Peers
The above table shows the PE ratio for NXTMH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average29.5x
BIOBV Biohit Oyj
45.4xn/a€22.7m
REG1V Revenio Group Oyj
50.3x19.4%€1.0b
ALEMG Euromedis Groupe
7.3x17.6%€16.4m
A058110 MEKICS
14.8xn/a₩66.8b
NXTMH Nexstim
7.8x-31.4%€25.8m

Price-To-Earnings vs Peers: NXTMH is good value based on its Price-To-Earnings Ratio (7.8x) compared to the peer average (29.5x).


Price to Earnings Ratio vs Industry

How does NXTMH's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Earnings vs Industry: NXTMH is good value based on its Price-To-Earnings Ratio (7.8x) compared to the European Medical Equipment industry average (24.8x)


Price to Earnings Ratio vs Fair Ratio

What is NXTMH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NXTMH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.8x
Fair PE Ratio6.3x

Price-To-Earnings vs Fair Ratio: NXTMH is expensive based on its Price-To-Earnings Ratio (7.8x) compared to the estimated Fair Price-To-Earnings Ratio (6.3x).


Share Price vs Fair Value

What is the Fair Price of NXTMH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NXTMH (€3.85) is trading below our estimate of fair value (€12.73)

Significantly Below Fair Value: NXTMH is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Nexstim forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-31.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXTMH's earnings are forecast to decline over the next 3 years (-31.4% per year).

Earnings vs Market: NXTMH's earnings are forecast to decline over the next 3 years (-31.4% per year).

High Growth Earnings: NXTMH's earnings are forecast to decline over the next 3 years.

Revenue vs Market: NXTMH's revenue is expected to decline over the next 3 years (-4.9% per year).

High Growth Revenue: NXTMH's revenue is forecast to decline over the next 3 years (-4.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NXTMH's Return on Equity is forecast to be high in 3 years time (31.8%)


Discover growth companies

Past Performance

How has Nexstim performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


30.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NXTMH has a high level of non-cash earnings.

Growing Profit Margin: NXTMH became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: NXTMH has become profitable over the past 5 years, growing earnings by 30.1% per year.

Accelerating Growth: NXTMH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NXTMH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2%).


Return on Equity

High ROE: NXTMH's Return on Equity (59.4%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Nexstim's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: NXTMH's short term assets (€8.9M) exceed its short term liabilities (€2.6M).

Long Term Liabilities: NXTMH's short term assets (€8.9M) exceed its long term liabilities (€3.3M).


Debt to Equity History and Analysis

Debt Level: NXTMH has more cash than its total debt.

Reducing Debt: NXTMH's debt to equity ratio has increased from 49.8% to 63.4% over the past 5 years.

Debt Coverage: NXTMH's debt is well covered by operating cash flow (62.7%).

Interest Coverage: NXTMH earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Nexstim current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NXTMH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXTMH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NXTMH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXTMH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NXTMH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Mikko Karvinen (46 yo)

2.58yrs

Tenure

Mr. Mikko Karvinen, M.Sc. (Econ.), serves as Chief Executive Officer at Nexstim Plc since June 16, 2020 and also served as an Interim Chief Executive Officer at Nexstim Plc since February 11, 2020 until Ju...


Leadership Team

Experienced Management: NXTMH's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: NXTMH's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 23 shareholders own 55.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.27%
Kaikarhenni Oy
1,022,416€3.9m0%no data
14.07%
Euroclear PLC, Asset Management Arm
942,029€3.6m0%0.06%
8.8%
Ossi Haapaniemi
589,222€2.3m0%no data
3.59%
Joensuun Kauppa Ja Kone Oy
240,241€924.9k0%no data
1.7%
Kalksten Properties Koy
114,124€439.4k0%no data
1.66%
Eva Syrjänen
110,940€427.1k0%no data
1.52%
WetRock Capital & Consulting Oy
101,573€391.1k0%no data
1.25%
Juha Valjakka
83,810€322.7k0%no data
1.04%
Kakkonen Ilmari
69,649€268.1k0%no data
0.97%
Pentti Niukkanen
65,000€250.3k0%no data
0.69%
Veijo Salmela
45,966€177.0k0%no data
0.65%
Kyosti Kakkonen
43,549€167.7k0%no data
0.6%
Jukka Jokinen
40,000€154.0k0%no data
0.58%
Harri Filen
38,551€148.4k0%no data
0.51%
Eero Kaukoranta
34,326€132.2k0%no data
0.45%
Harri Kivinen
30,200€116.3k0%no data
0.45%
Jan Pettersson
30,000€115.5k0%no data
0.44%
Skandinaviska Enskilda Banken AB, Private Banking, Investment Banking, and Insurance Arm
29,775€114.6k0%no data
0.39%
Matril Oy
25,884€99.7k0%no data
0.37%
Timo Niinisto
24,882€95.8k0%no data
0.27%
Reijo Himanka
18,200€70.1k0%no data
0.25%
Mero Antero
16,730€64.4k0%no data
0.22%
Elite Fund Management Ltd
14,928€57.5k0%0.42%

Company Information

Nexstim Plc's employee growth, exchange listings and data sources


Key Information

  • Name: Nexstim Plc
  • Ticker: NXTMH
  • Exchange: HLSE
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €25.771m
  • Shares outstanding: 6.69m
  • Website: https://www.nexstim.com

Number of Employees


Location

  • Nexstim Plc
  • ElimAeenkatu 9 B
  • Helsinki
  • Uusimaa
  • 510
  • Finland


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NXTMSOM (OMX Nordic Exchange Stockholm)YesA SharesSESEKNov 2014
NXTMHHLSE (OMX Nordic Exchange Helsinki)YesA SharesFIEURNov 2014
5NXDB (Deutsche Boerse AG)YesA SharesDEEURNov 2014

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/23 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.